CHMP Gives a Positive Opinion for the Use of Janssen-Cilag International NV's VELCADE® as Retreatment and for Frontline Induction Therapy Before Stem Cell Transplantation

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) has granted a positive opinion on two variations relating to the use of VELCADE®.1 VELCADE® is indicated for the treatment of multiple myeloma, a type of blood cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news